{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:47Z","timestamp":1793212127391,"version":"4.5.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T00:00:00Z","timestamp":1343174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0041529","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T22:11:56Z","timestamp":1343254316000},"page":"e41529","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":45,"title":["Intranasal Vaccination with Murabutide Enhances Humoral and Mucosal Immune Responses to a Virus-Like Particle Vaccine"],"prefix":"10.1371","volume":"7","author":[{"given":"Erin M.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Herbst-Kralovetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,7,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.","volume":"205","author":"M Kool","year":"2008","journal-title":"J Exp Med"},{"key":"ref2","first-page":"15","article-title":"The inflammasome and alum-mediated adjuvanticity.","volume":"1","author":"SJ Kang","year":"2009","journal-title":"F1000 Biol Rep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/eji.200940039","article-title":"The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants.","volume":"40","author":"R Spreafico","year":"2010","journal-title":"Eur J Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.","volume":"453","author":"SC Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/erv.10.142","article-title":"Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.","volume":"10","author":"AK Dey","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0264-410X(93)90190-9","article-title":"Adjuvants\u2013a balance between toxicity and adjuvanticity.","volume":"11","author":"RK Gupta","year":"1993","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1051\/vetres:2006014","article-title":"Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.","volume":"37","author":"E Cox","year":"2006","journal-title":"Vet Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1128\/CVI.00230-10","article-title":"An Intranasally Delivered Toll-Like Receptor 7 Agonist Elicits Robust Systemic and Mucosal Responses to Norwalk Virus-Like Particles.","volume":"17","author":"LS Velasquez","year":"2010","journal-title":"Clinical and Vaccine Immunology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1016\/j.vaccine.2011.05.027","article-title":"Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.","volume":"29","author":"LS Velasquez","year":"2011","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"9352","DOI":"10.1016\/j.vaccine.2011.09.129","article-title":"Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.","volume":"29","author":"SB Uppada","year":"2011","journal-title":"Vaccine"},{"key":"ref11","first-page":"157","article-title":"Control of IgE responses. II. Isotype specific suppression of peak hapten specific IgE antibody forming cell responses in BPO-KLH sensitized mice after oral administration of muramyldipeptide or murabutide.","volume":"26","author":"DL Auci","year":"1993","journal-title":"Immunopharmacology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd2783","article-title":"Unleashing the therapeutic potential of NOD-like receptors.","volume":"8","author":"K Geddes","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/IAI.44.2.344-350.1984","article-title":"Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs.","volume":"44","author":"NE Byars","year":"1984","journal-title":"Infect Immun"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/IAI.35.2.417-424.1982","article-title":"Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.","volume":"35","author":"LA Chedid","year":"1982","journal-title":"Infect Immun"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0192-0561(94)00094-5","article-title":"Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide.","volume":"17","author":"GM Bahr","year":"1995","journal-title":"Int J Immunopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/infdis\/153.3.628","article-title":"Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine.","volume":"153","author":"E Telzak","year":"1986","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/jac\/dkg244","article-title":"Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.","volume":"51","author":"GM Bahr","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.vaccine.2010.01.013","article-title":"Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.","volume":"28","author":"HJ Cho","year":"2010","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1006\/cyto.1996.0088","article-title":"Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue.","volume":"8","author":"EC Darcissac","year":"1996","journal-title":"Cytokine"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1128\/JVI.74.17.7794-7802.2000","article-title":"The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.","volume":"74","author":"EC Darcissac","year":"2000","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/IAI.45.1.261-266.1984","article-title":"Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.","volume":"45","author":"FM Audibert","year":"1984","journal-title":"Infect Immun"},{"key":"ref22","first-page":"PI43","article-title":"A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients naive to antiretrovirals.","volume":"9","author":"X De La Tribonniere","year":"2003","journal-title":"Med Sci Monit"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/1521-4141(200107)31:7<1962::AID-IMMU1962>3.0.CO;2-V","article-title":"Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C\/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.","volume":"31","author":"VF Vidal","year":"2001","journal-title":"Eur J Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.molimm.2004.06.012","article-title":"The role of Toll-like receptors and Nod proteins in bacterial infection.","volume":"41","author":"DJ Philpott","year":"2004","journal-title":"Mol Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11908-009-0080-9","article-title":"TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants.","volume":"12","author":"SC Higgins","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/ni1207-1269","article-title":"Bacterial cell walls, innate immunity and immunoadjuvants.","volume":"8","author":"JL Strominger","year":"2007","journal-title":"Nat Immunol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.crvi.2004.02.010","article-title":"Nods and \u2018intracellular\u2019 innate immunity.","volume":"327","author":"J Viala","year":"2004","journal-title":"C R Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2008.06.001","article-title":"NOD-like receptors (NLRs): bona fide intracellular microbial sensors.","volume":"20","author":"MH Shaw","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1179\/096805106X89044","article-title":"MDP and other muropeptides\u2013direct and synergistic effects on the immune system.","volume":"12","author":"S Traub","year":"2006","journal-title":"J Endotoxin Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"36223","DOI":"10.1074\/jbc.M703079200","article-title":"NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2.","volume":"282","author":"Y Yang","year":"2007","journal-title":"J Biol Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1128\/IAI.73.12.7967-7976.2005","article-title":"Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.","volume":"73","author":"H Tada","year":"2005","journal-title":"Infect Immun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2567.2001.01269.x","article-title":"Enhanced maturation and functional capacity of monocyte-derived immature dendritic cells by the synthetic immunomodulator Murabutide.","volume":"103","author":"V Vidal","year":"2001","journal-title":"Immunology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1515\/BC.2008.054","article-title":"Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.","volume":"389","author":"S Benko","year":"2008","journal-title":"Biol Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00126334-200207010-00005","article-title":"Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients.","volume":"30","author":"C Amiel","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref35","first-page":"193","article-title":"Immune and Antiviral Effects of the Synthetic Immunomodulator Murabutide Vaccine Adjuvants.","author":"GM Bahr","year":"2006"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkg063","article-title":"Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.","volume":"51","author":"GM Bahr","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0016-5085(99)70548-2","article-title":"Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.","volume":"117","author":"JM Ball","year":"1999","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"9713","DOI":"10.1128\/JVI.75.20.9713-9722.2001","article-title":"Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.","volume":"75","author":"RA Guerrero","year":"2001","journal-title":"J Virol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/erv.09.163","article-title":"Norwalk virus-like particles as vaccines.","volume":"9","author":"M Herbst-Kralovetz","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1101245","article-title":"Norovirus vaccine against experimental human Norwalk Virus illness.","volume":"365","author":"RL Atmar","year":"2011","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/656364","article-title":"Serological correlate of protection against norovirus-induced gastroenteritis.","volume":"202","author":"A Reeck","year":"2010","journal-title":"J Infect Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1128\/JVI.02179-09","article-title":"Heterotypic humoral and cellular immune responses following Norwalk virus infection.","volume":"84","author":"LC Lindesmith","year":"2010","journal-title":"J Virol"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0609.2012.01793.x","article-title":"Long term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies.","author":"J Mariotti","year":"2012"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1016\/j.biomaterials.2012.03.041","article-title":"Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.","volume":"33","author":"SL Demento","year":"2012","journal-title":"Biomaterials"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/mp2002494","article-title":"Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.","volume":"9","author":"R Ravindran","year":"2012","journal-title":"Mol Pharm"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4049\/jimmunol.1100783","article-title":"Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells.","volume":"188","author":"JB Foote","year":"2012","journal-title":"J Immunol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines.","volume":"11","author":"J Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"ref48","article-title":"Alum adjuvant: Some of the Tricks of the oldest adjuvant.","author":"M Kool","year":"2011"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/IAI.66.9.4163-4168.1998","article-title":"The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions.","volume":"66","author":"A Berneman","year":"1998","journal-title":"Infect Immun"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0165-0378(97)00081-8","article-title":"Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus.","volume":"38","author":"EL Parr","year":"1998","journal-title":"J Reprod Immunol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1073\/pnas.1012861108","article-title":"Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.","volume":"108","author":"Z Li","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0041529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T12:30:26Z","timestamp":1594470626000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0041529"}},"subtitle":[],"editor":[{"given":"Eliane Namie","family":"Miyaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,7,25]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,7,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0041529","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,25]]}}}